Julian G Westphal1, Thomas Winkens, Christian Kühnel, Martin Freesmeyer. 1. Clinic of Nuclear Medicine (J.G.W., T.W., C.K., M.F.), Jena University Hospital, 07743 Jena, Germany and Ernst-Abbe-Fachhochschule Jena (C.K.), University of Applied Sciences, 07740 Jena, Germany.
Abstract
CONTEXT: Radioiodine therapy of benign thyroid diseases requires pretherapy assessment of radioactive iodine uptake (RAIU) for reliable therapy planning. OBJECTIVE: Our objective was to assess RAIU by low-activity (124)I-positron emission tomography/low-dose computed tomography ((124)I-PET/CT) in comparison with standard (131)I probe measurements. DESIGN/ SETTING: This prospective comparative study was conducted at the Jena University Hospital, Jena, Germany, in a referral center setting. PATIENTS: A total of 79 patients with benign thyroid diseases were screened, 40 of whom met the inclusion criteria (stable TSH, free T3 and free T4 levels; no thyroid-specific medication, no iodine contamination) and 24 of whom agreed to participate by signing an informed consent. INTERVENTIONS: All patients received the standard (131)I scintillation probe uptake test 30 hours after administration of 3 MBq (131)I. Seven days later, all patients were subjected to (124)I-PET/CT uptake measurement 30 hours after administration of 1 MBq (124)I. MAIN OUTCOME MEASURES: The decay-corrected uptake values of both techniques were compared. Additionally, 3 different volume-of-interest-based evaluation methods in PET/CT (whole neck [WN], automatic isocontour [IC], and manually contoured [MC]) were evaluated. RESULTS: The (131)I probe measurement and (124)I-PET.WN method provided very similar mean RAIU (30.7% ± 10.3%; 31.7% ± 8.9%), resulting in a significant positive correlation (r = 0.93, P < .001). Compared with (124)I-PET.WN, the (124)I-PET.IC (29.8% ± 8.6%) and the (124)I-PET.MC (24.5% ± 7.1%) demonstrated lower uptake values. CONCLUSIONS: Using activities as low as 1 MBq, the (124)I-PET.WN method shows a good correlation with conventional (131)I probe measurement. Thus, (124)I-PET/CT is a suitable alternative for pretherapy RAIU evaluations. This may offer potential additional benefits such as PET/ultrasound fusion imaging and CT volumetry.
CONTEXT: Radioiodine therapy of benign thyroid diseases requires pretherapy assessment of radioactive iodine uptake (RAIU) for reliable therapy planning. OBJECTIVE: Our objective was to assess RAIU by low-activity (124)I-positron emission tomography/low-dose computed tomography ((124)I-PET/CT) in comparison with standard (131)I probe measurements. DESIGN/ SETTING: This prospective comparative study was conducted at the Jena University Hospital, Jena, Germany, in a referral center setting. PATIENTS: A total of 79 patients with benign thyroid diseases were screened, 40 of whom met the inclusion criteria (stable TSH, free T3 and free T4 levels; no thyroid-specific medication, no iodine contamination) and 24 of whom agreed to participate by signing an informed consent. INTERVENTIONS: All patients received the standard (131)I scintillation probe uptake test 30 hours after administration of 3 MBq (131)I. Seven days later, all patients were subjected to (124)I-PET/CT uptake measurement 30 hours after administration of 1 MBq (124)I. MAIN OUTCOME MEASURES: The decay-corrected uptake values of both techniques were compared. Additionally, 3 different volume-of-interest-based evaluation methods in PET/CT (whole neck [WN], automatic isocontour [IC], and manually contoured [MC]) were evaluated. RESULTS: The (131)I probe measurement and (124)I-PET.WN method provided very similar mean RAIU (30.7% ± 10.3%; 31.7% ± 8.9%), resulting in a significant positive correlation (r = 0.93, P < .001). Compared with (124)I-PET.WN, the (124)I-PET.IC (29.8% ± 8.6%) and the (124)I-PET.MC (24.5% ± 7.1%) demonstrated lower uptake values. CONCLUSIONS: Using activities as low as 1 MBq, the (124)I-PET.WN method shows a good correlation with conventional (131)I probe measurement. Thus, (124)I-PET/CT is a suitable alternative for pretherapy RAIU evaluations. This may offer potential additional benefits such as PET/ultrasound fusion imaging and CT volumetry.
Authors: Martin Freesmeyer; Thomas Winkens; Luis Weissenrieder; Christian Kühnel; Falk Gühne; Simone Schenke; Robert Drescher; Philipp Seifert Journal: Sensors (Basel) Date: 2020-06-17 Impact factor: 3.576
Authors: Martin Freesmeyer; Falk Gühne; Robert Drescher; Thomas Winkens; Nikolaus Gassler; Philipp Seifert Journal: Diagnostics (Basel) Date: 2022-02-12